LUCD

Lucid Diagnostics Inc. · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website luciddx.com
Employees(FY) -
ISIN US54948X1090

Performance

0.0%

+19.4%

+16.27%

+10.5%

-29.08%

YTD

-23.08%

Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma (EAC). It offers EsoCheck, a cell collection device to prevent EAC deaths; and EsoGuard, an Esophageal DNA Test. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Advanced Technical Analysis

Technical Analysis of LUCD 2024-11-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Technical Score of 73 further supports this positive outlook. However, the Oscillators Score of 56 suggests a more neutral stance, indicating potential consolidation or a pause in the upward trend.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of LUCD

Stock Rank

Recent News & Updates

2024-11-19 18:56
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard Esophageal DNA Test(Prnewswire)
2024-11-17 19:15
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum(Prnewswire)
2024-11-14 17:23
Q3 2024 PAVmed Inc Earnings Call(Yahoo Finance)
2024-11-14 13:09
PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring(Yahoo Finance)
2024-11-13 19:01
PAVmed Provides Business Update and Third Quarter 2024 Financial Results(Prnewswire)
2024-11-13 13:09
Lucid Diagnostics Inc (LUCD) Q3 2024 Earnings Call Highlights: Record Revenue Growth Amid ...(Yahoo Finance)
2024-11-12 19:01
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results(Prnewswire)
2024-11-06 19:01
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing Accepted for Peer-Reviewed Publication(Prnewswire)
2024-11-04 19:01
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers(Prnewswire)
2024-10-30 20:31
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024(Prnewswire)
2024-10-29 20:31
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024(Prnewswire)
2024-10-14 19:51
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test(Prnewswire)
2024-10-14 19:30
Castle Biosciences price target raised to $40 from $35 at BTIG(Yahoo Finance)
2024-10-08 20:01
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit(Prnewswire)
2024-10-07 19:49
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024(Prnewswire)
2024-09-30 20:01
Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL Players(Prnewswire)
2024-09-23 20:01
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test(Prnewswire)
2024-09-16 04:30
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements(Prnewswire)
2024-09-09 19:56
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress(Prnewswire)
2024-09-02 19:51
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health(Prnewswire)
2024-08-19 20:16
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard for Early Detection of Esophageal Precancer and Cancer(Prnewswire)
2024-08-13 14:28
Q2 2024 PAVmed Inc Earnings Call(Yahoo Finance)
2024-08-12 20:16
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard to Enhance Early Detection of Esophageal Cancer(Prnewswire)
2024-08-12 20:01
PAVmed Provides Business Update and Second Quarter 2024 Financial Results(Prnewswire)
2024-08-11 20:07
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results(Prnewswire)
2024-08-07 20:31
Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard #CheckYourFoodTube Precancer Testing Event(Prnewswire)
2024-08-05 20:15
Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard Esophageal Precancer Testing(Prnewswire)
2024-08-04 20:15
Lucid Diagnostics to Participate in Upcoming Investor Conferences(Prnewswire)
2024-07-29 20:15
PAVmed to Hold a Business Update Conference Call and Webcast on August 13, 2024(Prnewswire)
2024-07-28 20:15
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024(Prnewswire)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.